Overview


Heart disease remains the leading cause of mortality worldwide, yet there is encouraging news: the potential for early detection and prevention can significantly influence outcomes. With at-home heart health testing, individuals can actively monitor key indicators, such as cholesterol levels and blood pressure, without the need for a clinic visit. This approach not only empowers individuals to take charge of their health but also offers a cost-effective way to prioritize heart health. Embracing this proactive strategy enables one to stay informed and make informed decisions about well-being from the comfort of their own home.

FutureWise Market Research has instantiated a report that provides an intricate analysis of At Home Heart Health Testing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the At Home Heart Health Testing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abbott Laboratories
  • Sekisui Diagnostics LLC
  • Siemens Healthineers GmbH
  • Sinocare Inc.
  • Thermo Fisher Scientific Inc.
  • Omicron
  • Eurofins Scientific
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd 
  • Medtronic
  • Ascensia Diabetes Care
  • Arkray
  • Acon Laboratories
  • Ypsomed AG
  • Nipro
  • Nova Biomedical
  • Lifescan IP Holdings, LLC
  • Prodigy Diabetes Care
  • Beckman Coulter (Danaher Corp.)
  • Horiba Ltd
  • Mindray
  • Randox Laboratories Ltd.
  • Roche Holding AG (F. Hoffmann-La Roche Ltd.)

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product

  • Blood Pressure Monitors
  • Pulse Oximeters
  • Blood Glucose Devices
  • Cholesterol Testing Kits

By Sample

  • Blood
  • Saliva
  • Urine

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • E-commerce
  • Hypermarkets/Supermarkets

By End User

  • Individual Consumers
  • Elderly Care Facilities
  • Health-Conscious Individuals
  • Chronic Disease Patients

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the At Home Heart Health Testing Market By Product, By Sample, By Distribution Channel, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  At Home Heart Health Testing Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of At Home Heart Health Testing Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  At Home Heart Health Testing Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  At Home Heart Health Testing Market, By Product Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Blood Pressure Monitors
      2. Pulse Oximeters
      3. Blood Glucose Devices
      4. Cholesterol Testing Kits
  • 8.  At Home Heart Health Testing Market, By Sample Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Blood
      2. Saliva
      3. Urine
  • 9.  At Home Heart Health Testing Market, By Distribution Channel Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Retail Pharmacies
      2. Hospital Pharmacies
      3. E-commerce
      4. Hypermarkets/Supermarkets
  • 10.  At Home Heart Health Testing Market, By End User Historical Analysis and Forecast 2025-2033 (USD Million)
      1. Individual Consumers
      2. Elderly Care Facilities
      3. Health-Conscious Individuals
      4. Chronic Disease Patients
  • 11.  North America At Home Heart Health Testing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 12.  Latin America At Home Heart Health Testing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 13.  Europe At Home Heart Health Testing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 14.  Asia Pacific At Home Heart Health Testing Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 15.  Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Drug Types Offered and Financial Layouts)
    •    1. Abbott Laboratories
        1.1. Company Overview
        1.2. Drug Type Portfolio
        1.3. SWOT Analysis
        1.4. Financial Overview
        1.5. Strategic Overview
         2. Sekisui Diagnostics LLC
        2.1. Company Overview
        2.2. Drug Type Portfolio
        2.3. SWOT Analysis
        2.4. Financial Overview
        2.5. Strategic Overview
         3. Siemens Healthineers GmbH
        3.1. Company Overview
        3.2. Drug Type Portfolio
        3.3. SWOT Analysis
        3.4. Financial Overview
        3.5. Strategic Overview
         4. Sinocare Inc.
        4.1. Company Overview
        4.2. Drug Type Portfolio
        4.3. SWOT Analysis
        4.4. Financial Overview
        4.5. Strategic Overview
         5. Thermo Fisher Scientific Inc.
        5.1. Company Overview
        5.2. Drug Type Portfolio
        5.3. SWOT Analysis
        5.4. Financial Overview
        5.5. Strategic Overview
         6. Omicron
        6.1. Company Overview
        6.2. Drug Type Portfolio
        6.3. SWOT Analysis
        6.4. Financial Overview
        6.5. Strategic Overview
         7. Eurofins Scientific
        7.1. Company Overview
        7.2. Drug Type Portfolio
        7.3. SWOT Analysis
        7.4. Financial Overview
        7.5. Strategic Overview
         8. Dexcom, Inc.
        8.1. Company Overview
        8.2. Drug Type Portfolio
        8.3. SWOT Analysis
        8.4. Financial Overview
        8.5. Strategic Overview
         9. F. Hoffmann-La Roche Ltd 
        9.1. Company Overview
        9.2. Drug Type Portfolio
        9.3. SWOT Analysis
        9.4. Financial Overview
        9.5. Strategic Overview
        10. Medtronic
        10.1. Company Overview
        10.2. Drug Type Portfolio
        10.3. SWOT Analysis
        10.4. Financial Overview
        10.5. Strategic Overview
        11. Ascensia Diabetes Care
        11.1. Company Overview
        11.2. Drug Type Portfolio
        11.3. SWOT Analysis
        11.4. Financial Overview
        11.5. Strategic Overview
        12. Arkray
        12.1. Company Overview
        12.2. Drug Type Portfolio
        12.3. SWOT Analysis
        12.4. Financial Overview
        12.5. Strategic Overview
        13. Acon Laboratories
        13.1. Company Overview
        13.2. Drug Type Portfolio
        13.3. SWOT Analysis
        13.4. Financial Overview
        13.5. Strategic Overview
        14. Ypsomed AG
        14.1. Company Overview
        14.2. Drug Type Portfolio
        14.3. SWOT Analysis
        14.4. Financial Overview
        14.5. Strategic Overview
        15. Nipro
        15.1. Company Overview
        15.2. Drug Type Portfolio
        15.3. SWOT Analysis
        15.4. Financial Overview
        15.5. Strategic Overview
        16. Nova Biomedical
        16.1. Company Overview
        16.2. Drug Type Portfolio
        16.3. SWOT Analysis
        16.4. Financial Overview
        16.5. Strategic Overview
        17. Lifescan IP Holdings, LLC
        17.1. Company Overview
        17.2. Drug Type Portfolio
        17.3. SWOT Analysis
        17.4. Financial Overview
        17.5. Strategic Overview
        18. Prodigy Diabetes Care
        18.1. Company Overview
        18.2. Drug Type Portfolio
        18.3. SWOT Analysis
        18.4. Financial Overview
        18.5. Strategic Overview
        19. Beckman Coulter (Danaher Corp.)
        19.1. Company Overview
        19.2. Drug Type Portfolio
        19.3. SWOT Analysis
        19.4. Financial Overview
        19.5. Strategic Overview
        20. Horiba Ltd
        20.1. Company Overview
        20.2. Drug Type Portfolio
        20.3. SWOT Analysis
        20.4. Financial Overview
        20.5. Strategic Overview
        21. Mindray
        21.1. Company Overview
        21.2. Drug Type Portfolio
        21.3. SWOT Analysis
        21.4. Financial Overview
        21.5. Strategic Overview
        22. Randox Laboratories Ltd.
        22.1. Company Overview
        22.2. Drug Type Portfolio
        22.3. SWOT Analysis
        22.4. Financial Overview
        22.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •     

Partner

Our Clients